Introduction
Materials and methods
Ethics statement
Patients and procedures
Chemotherapy
External beam radiotherapy
Follow-up evaluation
Statistical analysis
Results
Clinical baseline characteristics
Variables | Number | Percentage |
---|---|---|
Age, years | ||
≥ 49 | 20 | 46.5% |
< 49 | 23 | 53.5% |
FIGO stage | ||
IB1 | 11 | 25.6% |
IB2 | 14 | 32.6% |
IIA1 | 9 | 20.9% |
IIA2 | 9 | 20.9% |
Tumor biology | ||
pure | 31 | 72.1% |
mix | 12 | 27.9% |
Lymph node metastasis | ||
yes | 19 | 44.2% |
no | 24 | 55.8% |
Adjuvant radiation | ||
yes | 28 | 65.1% |
no | 15 | 34.9% |
Tumor size, cm | ||
≥ 4 | 23 | 53.5% |
< 4 | 20 | 46.5% |
LVSI | ||
yes | 23 | 53.5% |
no | 20 | 46.5% |
Chemotherapy regimen | ||
TP | 30 | 69.8% |
EP | 13 | 30.2% |
Survival analysis for the whole group
Univariate and multivariable analysis of DFS and OS for the whole group
Variable | Number of patients | 5-year DFS | P value | 5-year OS | P value |
---|---|---|---|---|---|
Age, year | 0.063 | 0.044 | |||
≥ 49 | 20 | 15.0% | 25.0% | ||
< 49 | 23 | 39.1% | 50.6% | ||
FIGO Stage | 0.352 | 0.414 | |||
I | 25 | 28.0% | 34.3% | ||
II | 18 | 27.8% | 44.4% | ||
Tumor biology | 0.398 | 0.554 | |||
pure | 31 | 25.8% | 38.7% | ||
mixed | 12 | 33.3% | 38.9% | ||
Lymph node metastasis | 0.003 | 0.035 | |||
yes | 19 | 10.5% | 31.6% | ||
no | 24 | 41.7% | 44.9% | ||
Adjuvant radiation | 0.038 | 0.097 | |||
yes | 28 | 35.7% | 42.9% | ||
no | 15 | 13.3% | 31.1% | ||
Tumor size, cm | 0.342 | 0.116 | |||
≥ 4 | 23 | 26.1% | 30.4% | ||
< 4 | 20 | 30.0% | 48.7% | ||
LVSI | 0.388 | 0.209 | |||
yes | 23 | 26.1% | 33.8% | ||
no | 20 | 30.0% | 45.0% |
Variable | DFS | OS | ||
---|---|---|---|---|
HR(95%CI) | P value | HR(95%CI) | P value | |
Lymph node metastasis no vs yes | 0.282 (0.136–0.588) | 0.001 | 0.326 (0.153–0.695) | 0.004 |
Adjuvant radiation yes vs no | 0.383 (0.185–0.791) | 0.009 | _ | |
Age, year < 49 vs ≥49 | _ | 0.329 (0.154–0.703) | 0.004 |
Subgroup analysis based on clinical factor of adjuvant radiation
Variable | Adjuvant radiation (n = 28) | Non-adjuvant radiation (n = 15) | P value |
---|---|---|---|
Age, years | 0.988 | ||
≥ 49 | 13 | 7 | |
< 49 | 15 | 8 | |
Tumor size, cm | 0.512 | ||
≥ 4 | 16 | 7 | |
< 4 | 12 | 8 | |
FIGO stage | 0.640 | ||
I (IB1 and IB2) | 17 | 8 | |
II (IIA1 and IIA2) | 11 | 7 | |
Lymph node metastasis | 0.126 | ||
yes | 10 | 9 | |
no | 18 | 6 | |
LVSI | 0.056 | ||
yes | 12 | 11 | |
no | 16 | 4 | |
Chemotherapy regimen | 0.745 | ||
EP | 9 | 4 | |
TP | 19 | 11 | |
Overall follow up, months Median (range) | 59 (12–131) | 45 (9–102) | 0.120 |
Group | Adjuvant radiation | Non-adjuvant radiation | P value |
---|---|---|---|
5-year | 5-year | ||
LR | 3 (10.7%) | 9 (60.0%) | < 0.001a |
SM | 15 (53.6%) | 8 (53.3%) | 0.772a |